Adrenomedullin (ADM) (ADM)

Adrenomedullin (ADM) is a 52-amino acid peptide hormone belonging to the calcitonin gene-related peptide (CGRP) family, primarily known for its potent vasodilatory and angiogenic properties [1]. It is widely expressed in the cardiovascular system, particularly by endothelial and smooth muscle cells, where it acts via the calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying proteins (RAMP2 and RAMP3) [1, 4]. While ADM is essential for maintaining vascular tone and endothelial barrier function, its overexpression is linked to pathological states such as sepsis, where it contributes to hypotension, and cancer, where it promotes tumor angiogenesis and progression [2, 4]. Targeting ADM through vaccine-induced antibodies represents an active immunotherapy approach designed to elicit a sustained endogenous immune response to neutralize excess circulating ADM [2, 3]. This strategy aims to stabilize vascular permeability in acute inflammatory conditions or inhibit the blood supply to tumors in oncological settings [3, 4]. By inducing antibodies that sequester ADM within the vasculature or neutralize its activity, researchers hope to prevent the deleterious effects of ADM overproduction while maintaining its protective roles [4].

Other names

AMPreproadrenomedullinADM1

Induction of endogenous neutralizing antibodies through active immunization to sequester circulating adrenomedullin, thereby preventing its binding to CALCRL/RAMP receptor complexes and modulating vascular permeability and angiogenesis.